# HIPEC After Initial CRS in Patients Who Have Received NACT

> **NCT03540017** · PHASE1 · UNKNOWN · sponsor: **Northwell Health** · enrollment: 15 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03540017
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-12
- **Primary completion:** 2024-07-05
- **Final completion:** 2025-07-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540017, "HIPEC After Initial CRS in Patients Who Have Received NACT". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03540017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*